# DocGo Inc.: financial statements, quarterly

DCGO · Nasdaq · CIK 1822359 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dcgo.md) · [Financials](/companies/dcgo/financials.md) · [Filings](/companies/dcgo/filings.md) · [Insiders](/companies/dcgo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dcgo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [187](/filings/0001822359-24-000094.md) | [199 d](/filings/0001628280-26-018214.md) | [192](/filings/0001822359-25-000042.md) | [165](/filings/0001822359-25-000074.md) | [139](/filings/0001628280-25-051102.md) | [121 d](/filings/0001628280-26-018214.md) | [96.0](/filings/0001628280-26-033563.md) | [80.4](/filings/0001628280-26-057394.md) | [70.8](/filings/0001628280-25-051102.md) | [74.9 d](/filings/0001628280-26-018214.md) | [75.6](/filings/0001628280-26-033563.md) | [73.4](/filings/0001628280-26-057394.md) |
| Research and development | $m | [3.2](/filings/0001822359-24-000094.md) | [3.2 d](/filings/0001628280-26-018214.md) | [2.4](/filings/0001822359-25-000042.md) | [2.4](/filings/0001822359-25-000074.md) | [3.1](/filings/0001628280-25-051102.md) | [3.7 d](/filings/0001628280-26-018214.md) | [3.6](/filings/0001628280-26-033563.md) | [3.0](/filings/0001628280-26-057394.md) | [3.2](/filings/0001628280-25-051102.md) | [3.8 d](/filings/0001628280-26-018214.md) | [3.7](/filings/0001628280-26-033563.md) | [3.4](/filings/0001628280-26-057394.md) |
| Operating income | $m | [8.7](/filings/0001822359-24-000094.md) | [11.7 d](/filings/0001628280-26-018214.md) | [15.9](/filings/0001822359-25-000042.md) | [10.1](/filings/0001822359-25-000074.md) | [10.1](/filings/0001628280-25-051102.md) | [(7.5) d](/filings/0001628280-26-018214.md) | [(14.0)](/filings/0001628280-26-033563.md) | [(17.5)](/filings/0001628280-26-057394.md) | [(42.0)](/filings/0001628280-25-051102.md) | [(105) d](/filings/0001628280-26-018214.md) | [(18.7)](/filings/0001628280-26-033563.md) | [(17.9)](/filings/0001628280-26-057394.md) |
| Income tax | $m | [4.5](/filings/0001822359-24-000094.md) | [4.2 d](/filings/0001628280-26-018214.md) | [5.1](/filings/0001822359-25-000042.md) | [3.7](/filings/0001822359-25-000074.md) | [4.5](/filings/0001628280-25-051102.md) | [1.1 d](/filings/0001628280-26-018214.md) | [(3.7)](/filings/0001628280-26-033563.md) | [(4.6)](/filings/0001628280-26-057394.md) | [(13.5)](/filings/0001628280-25-051102.md) | [30.7 d](/filings/0001628280-26-018214.md) | [0.0](/filings/0001628280-26-033563.md) | [0.1](/filings/0001628280-26-057394.md) |
| Net income | $m | [4.6](/filings/0001822359-24-000094.md) | [4.8 d](/filings/0001628280-26-018214.md) | [11.2](/filings/0001628280-25-051102.md) | [6.5](/filings/0001628280-25-051102.md) | [5.5](/filings/0001628280-25-051102.md) | [(3.3) d](/filings/0001628280-26-018214.md) | [(9.4)](/filings/0001628280-26-057394.md) | [(11.2)](/filings/0001628280-26-057394.md) | [(27.8)](/filings/0001628280-25-051102.md) | [(134) d](/filings/0001628280-26-018214.md) | [(14.8)](/filings/0001628280-26-057394.md) | [(15.8)](/filings/0001628280-26-057394.md) |
| Diluted EPS | $ per share | [0.05](/filings/0001822359-24-000094.md) | not reported | [0.10](/filings/0001822359-25-000042.md) | [0.06](/filings/0001822359-25-000074.md) | [0.05](/filings/0001628280-25-051102.md) | not reported | [(0.09)](/filings/0001628280-26-033563.md) | [(0.11)](/filings/0001628280-26-057394.md) | [(0.28)](/filings/0001628280-25-051102.md) | not reported | [(0.15)](/filings/0001628280-26-033563.md) | [(0.16)](/filings/0001628280-26-057394.md) |
| Basic EPS | $ per share | [0.05](/filings/0001822359-24-000094.md) | not reported | [0.11](/filings/0001822359-25-000042.md) | [0.06](/filings/0001822359-25-000074.md) | [0.05](/filings/0001628280-25-051102.md) | not reported | [(0.09)](/filings/0001628280-26-033563.md) | [(0.11)](/filings/0001628280-26-057394.md) | [(0.28)](/filings/0001628280-25-051102.md) | not reported | [(0.15)](/filings/0001628280-26-033563.md) | [(0.16)](/filings/0001628280-26-057394.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss, us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [52.9](/filings/0001822359-24-000094.md) | [59.3](/filings/0001628280-26-018214.md) | [41.2](/filings/0001822359-25-000042.md) | [66.1](/filings/0001822359-25-000074.md) | [89.5](/filings/0001628280-25-051102.md) | [89.2](/filings/0001628280-26-018214.md) | [79.0](/filings/0001628280-26-033563.md) | [104](/filings/0001628280-26-057394.md) | [73.4](/filings/0001628280-25-051102.md) | [51.0](/filings/0001628280-26-057394.md) | [35.7](/filings/0001628280-26-033563.md) | [25.2](/filings/0001628280-26-057394.md) |
| Current assets | $m | [267](/filings/0001822359-23-000032.md) | [339](/filings/0001822359-25-000018.md) | [335](/filings/0001822359-24-000045.md) | [329](/filings/0001822359-24-000081.md) | [328](/filings/0001822359-24-000094.md) | [304](/filings/0001628280-26-018214.md) | [263](/filings/0001822359-25-000042.md) | [237](/filings/0001822359-25-000074.md) | [190](/filings/0001628280-25-051102.md) | [152](/filings/0001628280-26-057394.md) | [138](/filings/0001628280-26-033563.md) | [120](/filings/0001628280-26-057394.md) |
| Total assets | $m | [420](/filings/0001822359-24-000094.md) | [490](/filings/0001628280-26-018214.md) | [491](/filings/0001822359-25-000042.md) | [488](/filings/0001822359-25-000074.md) | [494](/filings/0001628280-25-051102.md) | [456](/filings/0001628280-26-018214.md) | [431](/filings/0001628280-26-033563.md) | [408](/filings/0001628280-26-057394.md) | [354](/filings/0001628280-25-051102.md) | [217](/filings/0001628280-26-057394.md) | [209](/filings/0001628280-26-033563.md) | [187](/filings/0001628280-26-057394.md) |
| Current liabilities | $m | [113](/filings/0001822359-23-000032.md) | [170](/filings/0001822359-25-000018.md) | [160](/filings/0001822359-24-000045.md) | [154](/filings/0001822359-24-000081.md) | [150](/filings/0001822359-24-000094.md) | [122](/filings/0001628280-26-018214.md) | [108](/filings/0001822359-25-000042.md) | [100](/filings/0001822359-25-000074.md) | [73.6](/filings/0001628280-25-051102.md) | [67.5](/filings/0001628280-26-057394.md) | [77.2](/filings/0001628280-26-033563.md) | [72.3](/filings/0001628280-26-057394.md) |
| Total liabilities | $m | [128](/filings/0001822359-23-000032.md) | [185](/filings/0001822359-25-000018.md) | [176](/filings/0001822359-24-000045.md) | [170](/filings/0001822359-24-000081.md) | [169](/filings/0001822359-24-000094.md) | [140](/filings/0001628280-26-018214.md) | [129](/filings/0001822359-25-000042.md) | [121](/filings/0001822359-25-000074.md) | [93.1](/filings/0001628280-25-051102.md) | [91.2](/filings/0001628280-26-057394.md) | [98.0](/filings/0001628280-26-033563.md) | [91.0](/filings/0001628280-26-057394.md) |
| Long-term debt | $m | [2.0](/filings/0001822359-23-000032.md) | [0.0](/filings/0001822359-24-000016.md) | [0.0](/filings/0001822359-24-000045.md) | [0.0](/filings/0001822359-24-000081.md) | [0.0](/filings/0001822359-24-000094.md) | [0.0](/filings/0001822359-25-000018.md) | [0.0](/filings/0001822359-25-000042.md) | [0.0](/filings/0001822359-25-000074.md) | [0.2](/filings/0001628280-25-051102.md) | [0.2](/filings/0001628280-26-018214.md) | [0.2](/filings/0001628280-26-033563.md) | [0.2](/filings/0001628280-26-057394.md) |
| Current portion of debt | $m | [0.7](/filings/0001822359-23-000032.md) | [0.0](/filings/0001822359-24-000016.md) | [0.0](/filings/0001822359-24-000045.md) | [0.0](/filings/0001822359-24-000081.md) | [0.0](/filings/0001822359-24-000094.md) | [0.0](/filings/0001822359-25-000018.md) | [0.0](/filings/0001822359-25-000042.md) | [0.0](/filings/0001822359-25-000074.md) | [0.1](/filings/0001628280-25-051102.md) | [0.1](/filings/0001628280-26-018214.md) | [0.0](/filings/0001628280-26-033563.md) | [0.0](/filings/0001628280-26-057394.md) |
| Shareholders' equity | $m | [288](/filings/0001822359-23-000032.md) | [301](/filings/0001822359-25-000018.md) | [311](/filings/0001822359-24-000045.md) | [315](/filings/0001822359-24-000081.md) | [325](/filings/0001822359-24-000094.md) | [321](/filings/0001628280-26-018214.md) | [309](/filings/0001822359-25-000042.md) | [297](/filings/0001822359-25-000074.md) | [271](/filings/0001628280-25-051102.md) | [144](/filings/0001628280-26-057394.md) | [132](/filings/0001628280-26-033563.md) | [119](/filings/0001628280-26-057394.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(45.9) d](/filings/0001822359-24-000094.md) | [(6.2) d](/filings/0001628280-26-018214.md) | [(10.6)](/filings/0001822359-25-000042.md) | [36.9 d](/filings/0001822359-25-000074.md) | [31.1 d](/filings/0001628280-25-051102.md) | [12.7 d](/filings/0001628280-26-018214.md) | [9.2](/filings/0001628280-26-033563.md) | [34.0 d](/filings/0001628280-26-057394.md) | [1.7 d](/filings/0001628280-25-051102.md) | [(10.5) d](/filings/0001628280-26-018214.md) | [(4.7)](/filings/0001628280-26-033563.md) | [(9.2) d](/filings/0001628280-26-057394.md) |
| Capital expenditure | $m | [5.5](/filings/0001822359-24-000094.md) | [3.0 d](/filings/0001628280-26-018214.md) | [1.0](/filings/0001822359-25-000042.md) | [4.8](/filings/0001822359-24-000081.md) | [4.2](/filings/0001822359-24-000094.md) | [0.7 d](/filings/0001628280-26-018214.md) | [1.0](/filings/0001628280-26-033563.md) | [1.1 d](/filings/0001628280-26-057394.md) | [0.9 d](/filings/0001628280-25-051102.md) | [1.5 d](/filings/0001628280-26-018214.md) | [0.4](/filings/0001628280-26-033563.md) | [0.3 d](/filings/0001628280-26-057394.md) |
| Share repurchases | $m | [0.0 d](/filings/0001822359-24-000094.md) | [0.0 d](/filings/0001628280-26-018214.md) | [4.9](/filings/0001822359-25-000042.md) | [4.9 d](/filings/0001822359-25-000074.md) | [1.3 d](/filings/0001628280-25-051102.md) | [2.7 d](/filings/0001628280-26-018214.md) | [5.8](/filings/0001628280-26-033563.md) | [5.1 d](/filings/0001628280-26-057394.md) | [0.0 d](/filings/0001628280-25-051102.md) | [0.0 d](/filings/0001628280-26-018214.md) | [0.0](/filings/0001628280-26-033563.md) | [0.0 d](/filings/0001628280-26-057394.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets, us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [107](/filings/0001822359-23-000032.md) | [103](/filings/0001822359-24-000045.md) | [104](/filings/0001822359-24-000081.md) | [105](/filings/0001822359-24-000094.md) | [109](/filings/0001822359-25-000042.md) | [106](/filings/0001822359-25-000074.md) | [106](/filings/0001628280-25-051102.md) | [102](/filings/0001628280-26-033563.md) | [98.9](/filings/0001628280-26-057394.md) | [97.8](/filings/0001628280-25-051102.md) | [98.7](/filings/0001628280-26-033563.md) | [98.8](/filings/0001628280-26-057394.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 98,928,369 at 2026-08-14, from the cover of the [10-Q filed 2026-08-17](/filings/0001628280-26-057394.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.